Radius Health Company Profile (NASDAQ:RDUS)

About Radius Health (NASDAQ:RDUS)

Radius Health logoRadius Health, Inc. is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company's lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Company's clinical pipeline also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug elacestrant (RAD1901) for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Its RAD140 is a non-steroidal, selective androgen receptor modulator (SARM). RAD140 is under development for potential use in hormone receptor positive breast cancer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:RDUS
  • CUSIP: N/A
  • Web: www.radiuspharm.com
Capitalization:
  • Market Cap: $1.50568 billion
  • Outstanding Shares: 43,504,000
Average Prices:
  • 50 Day Moving Avg: $36.54
  • 200 Day Moving Avg: $38.62
  • 52 Week Range: $31.58 - $55.97
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.67
  • P/E Growth: -0.16
Sales & Book Value:
  • Annual Revenue: $980,000.00
  • Price / Sales: 1,535.96
  • Book Value: $4.77 per share
  • Price / Book: 7.25
Profitability:
  • EBITDA: ($225,190,000.00)
  • Return on Equity: -79.46%
  • Return on Assets: -71.59%
Debt:
  • Current Ratio: 7.04%
  • Quick Ratio: 6.99%
Misc:
  • Average Volume: 955,706 shs.
  • Beta: 1.33
  • Short Ratio: 9.34
 

Frequently Asked Questions for Radius Health (NASDAQ:RDUS)

What is Radius Health's stock symbol?

Radius Health trades on the NASDAQ under the ticker symbol "RDUS."

How were Radius Health's earnings last quarter?

Radius Health, Inc. (NASDAQ:RDUS) posted its quarterly earnings results on Thursday, August, 3rd. The company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.35) by $0.23. The company had revenue of $0.98 million for the quarter, compared to analyst estimates of $1.96 million. During the same period in the prior year, the company posted ($1.01) EPS. View Radius Health's Earnings History.

Where is Radius Health's stock going? Where will Radius Health's stock price be in 2017?

8 brokerages have issued 12 month price objectives for Radius Health's shares. Their forecasts range from $24.00 to $85.00. On average, they anticipate Radius Health's share price to reach $52.17 in the next year. View Analyst Ratings for Radius Health.

What are analysts saying about Radius Health stock?

Here are some recent quotes from research analysts about Radius Health stock:

  • 1. According to Zacks Investment Research, "The FDA’s approval of Radius Health’s lead candidate, Tymlos, is a significant boost for the company. The company is moving ahead with its plans in contracting with managed care organizations with access to over 133 million covered lives across Commercial and Medicare Part D plans. Although the osteoporosis market in the U.S. has a great potential as approximately 1.4 million postmenopausal women in the U.S. experience an osteoporotic fracture each year, Tymlos is expected to face significant competition from Eli Lilly &Co's Forteo and Amgen’s Prolia. Further, the company suffered a setback when the CHMP issued a second Day-180 List of Outstanding Issues to its MAA for Eladynos in Europe. While Radius' efforts in developing its pipeline are encouraging, we note that most of its candidates are in their early or mid stages of development. The company’ shares have underperformed the industry in the year so far." (10/4/2017)
  • 2. Canaccord Genuity analysts commented, "Date and time of first dissemination: July 31, 2017, 12:01 ET Date and time of production: July 31, 2017, 12:01 ET Target Price / Valuation Methodology: Radius Health – RDUS Our $85 price target is based on a probability adjusted EV/S methodology." (7/31/2017)
  • 3. Cantor Fitzgerald analysts commented, "RDUS shares are rallying this morning (+2%) on FDA approval of TYMLOS (abaloparatide-SC) ahead of expectations, as the extended PDUFA was June." (4/28/2017)

Who are some of Radius Health's key competitors?

Who are Radius Health's key executives?

Radius Health's management team includes the folowing people:

  • Kurt C. Graves, Independent Chairman of the Board
  • Jesper Hoiland, President, Chief Executive Officer, Director
  • Jose Carmona, Chief Financial Officer, Principal Accounting Officer, Treasurer
  • Gary Hattersley Ph.D., Senior Vice President, Chief Scientific Officer
  • Brent Hatzis-Schoch, Senior Vice President, General Counsel, Secretary
  • Lorraine A. Fitzpatrick M.D., Chief Medical Officer
  • David P. Snow, Chief Commercial Officer
  • Gregory Williams Ph.D., Chief Development Officer
  • Alan H. Auerbach, Independent Director
  • Willard H. Dere M.D., Independent Director

How do I buy Radius Health stock?

Shares of Radius Health can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Radius Health's stock price today?

One share of Radius Health stock can currently be purchased for approximately $34.60.


MarketBeat Community Rating for Radius Health (NASDAQ RDUS)
Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  272 (Vote Outperform)
Underperform Votes:  146 (Vote Underperform)
Total Votes:  418
MarketBeat's community ratings are surveys of what our community members think about Radius Health and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Radius Health (NASDAQ:RDUS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Hold Ratings, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.63)
Consensus Price Target: $52.17 (50.77% upside)
Consensus Price Target History for Radius Health (NASDAQ:RDUS)
Price Target History for Radius Health (NASDAQ:RDUS)
Analysts' Ratings History for Radius Health (NASDAQ:RDUS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/6/2017Goldman Sachs Group, Inc. (The)Reiterated RatingNeutral -> Neutral$45.00N/AView Rating Details
9/29/2017Maxim GroupReiterated RatingPositiveMediumView Rating Details
8/9/2017Jefferies Group LLCReiterated RatingHold$34.00 -> $38.00HighView Rating Details
7/31/2017Canaccord GenuitySet Price TargetBuy$85.00MediumView Rating Details
7/23/2017Cantor FitzgeraldSet Price TargetBuy$58.00MediumView Rating Details
5/15/2017HC WainwrightReiterated RatingBuy$63.00LowView Rating Details
5/2/2017Cowen and CompanyDowngradeOutperform -> Market PerformLowView Rating Details
3/11/2017J P Morgan Chase & CoReiterated RatingBuyMediumView Rating Details
1/25/2016Bank of America CorporationReiterated RatingBuy$89.00N/AView Rating Details
(Data available from 10/19/2015 forward)

Earnings

Earnings History for Radius Health (NASDAQ:RDUS)
Earnings by Quarter for Radius Health (NASDAQ:RDUS)
Earnings History by Quarter for Radius Health (NASDAQ RDUS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/3/2017Q2 2017($1.35)($1.58)$1.96 million$0.98 millionViewListenView Earnings Details
5/4/2017Q1 2017($1.18)($1.32)ViewListenView Earnings Details
2/23/2017Q416($1.34)($1.22)ViewN/AView Earnings Details
11/3/2016Q316($1.03)($1.07)$0.75 millionViewN/AView Earnings Details
8/4/2016Q216($0.95)($1.01)ViewN/AView Earnings Details
5/5/2016Q116($0.74)($0.94)ViewN/AView Earnings Details
2/25/2016Q415($0.64)($0.77)ViewListenView Earnings Details
11/5/2015Q315($0.58)($0.68)ViewN/AView Earnings Details
8/6/2015Q215($0.52)($0.61)ViewN/AView Earnings Details
5/6/2015Q115($0.52)($0.47)ViewN/AView Earnings Details
3/10/2015Q414($0.63)($0.55)ViewN/AView Earnings Details
11/10/2014Q314($0.65)($0.59)ViewN/AView Earnings Details
8/12/2014Q2($0.89)($2.22)$16.24 million$10.62 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Radius Health (NASDAQ:RDUS)
2017 EPS Consensus Estimate: ($4.82)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.94)($0.94)($0.94)
Q2 20171($1.37)($1.37)($1.37)
Q3 20171($1.31)($1.31)($1.31)
Q4 20171($1.20)($1.20)($1.20)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Radius Health (NASDAQ:RDUS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Radius Health (NASDAQ:RDUS)
Insider Ownership Percentage: 15.00%
Insider Trades by Quarter for Radius Health (NASDAQ:RDUS)
Institutional Ownership by Quarter for Radius Health (NASDAQ:RDUS)
Insider Trades by Quarter for Radius Health (NASDAQ:RDUS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/15/2017Jesper HoilandInsiderBuy6,100$32.72$199,592.00View SEC Filing  
9/14/2017Growth N V BiotechMajor ShareholderBuy150,000$33.45$5,017,500.00View SEC Filing  
9/14/2017Jose CarmonaCFOBuy3,000$32.83$98,490.00View SEC Filing  
9/12/2017Growth N V BiotechMajor ShareholderBuy50,000$35.42$1,771,000.00View SEC Filing  
9/5/2017Growth N V BiotechMajor ShareholderBuy50,000$36.75$1,837,500.00View SEC Filing  
8/16/2017Growth N V BiotechMajor ShareholderBuy60,000$35.98$2,158,800.00View SEC Filing  
8/10/2017Growth N V BiotechMajor ShareholderBuy150,000$34.97$5,245,500.00View SEC Filing  
5/30/2017Growth N V BiotechMajor ShareholderBuy40,000$34.21$1,368,400.00View SEC Filing  
5/25/2017Growth N V BiotechMajor ShareholderBuy40,000$36.25$1,450,000.00View SEC Filing  
5/18/2017Growth N V BiotechMajor ShareholderBuy50,000$34.41$1,720,500.00View SEC Filing  
5/17/2017Growth N V BiotechMajor ShareholderBuy35,000$33.44$1,170,400.00View SEC Filing  
5/12/2017Growth N V BiotechMajor ShareholderBuy15,000$34.00$510,000.00View SEC Filing  
5/9/2017Growth N V BiotechMajor ShareholderBuy50,000$35.93$1,796,500.00View SEC Filing  
5/8/2017Growth N V BiotechMajor ShareholderBuy43,400$35.57$1,543,738.00View SEC Filing  
5/2/2017Growth N V BiotechMajor ShareholderBuy75,000$33.91$2,543,250.00View SEC Filing  
5/1/2017Growth N V BiotechMajor ShareholderBuy150,000$35.39$5,308,500.00View SEC Filing  
3/21/2017Growth N V BiotechMajor ShareholderBuy50,000$35.83$1,791,500.00View SEC Filing  
3/17/2017Growth N V BiotechMajor ShareholderBuy30,000$38.41$1,152,300.00View SEC Filing  
3/15/2017Growth N V BiotechMajor ShareholderBuy61,721$39.97$2,466,988.37View SEC Filing  
3/10/2017Growth N V BiotechMajor ShareholderBuy38,279$39.17$1,499,388.43View SEC Filing  
1/22/2016Growth N V BiotechMajor ShareholderBuy38,259$31.67$1,211,662.53View SEC Filing  
1/13/2016Growth N V BiotechMajor ShareholderBuy50,000$39.90$1,995,000.00View SEC Filing  
11/12/2015Gary HattersleyinsiderSell5,683$75.00$426,225.00View SEC Filing  
11/3/2015Gary HattersleyinsiderSell13,333$70.00$933,310.00View SEC Filing  
10/23/2015Gary HattersleyinsiderSell11,302$65.00$734,630.00View SEC Filing  
10/21/2015Gary HattersleyinsiderSell1,501$65.36$98,105.36View SEC Filing  
10/21/2015Rob WardCEOSell50,000$61.99$3,099,500.00View SEC Filing  
8/21/2015Growth N. V. Biotechmajor shareholderBuy100,000$64.00$6,400,000.00View SEC Filing  
8/17/2015Kurt GravesDirectorSell22,694$70.00$1,588,580.00View SEC Filing  
7/6/2015Kurt GravesDirectorSell25,000$69.48$1,737,000.00View SEC Filing  
6/18/2015Kurt GravesDirectorSell25,000$55.05$1,376,250.00View SEC Filing  
5/1/2015Growth N V BiotechMajor ShareholderBuy50,000$36.46$1,823,000.00View SEC Filing  
4/29/2015Growth N V BiotechMajor ShareholderBuy50,000$36.23$1,811,500.00View SEC Filing  
4/28/2015Growth N V BiotechMajor ShareholderBuy50,000$36.59$1,829,500.00View SEC Filing  
4/27/2015Growth N V BiotechMajor ShareholderBuy50,000$38.38$1,919,000.00View SEC Filing  
3/6/2015Growth N V BiotechMajor ShareholderBuy75,000$47.08$3,531,000.00View SEC Filing  
2/25/2015Growth N V BiotechMajor ShareholderBuy35,000$45.74$1,600,900.00View SEC Filing  
6/11/2014Morana Jovan-EmbiricosDirectorBuy587,500$8.00$4,700,000.00View SEC Filing  
6/6/2014Growth N V BiotechMajor ShareholderBuy1,000,000$8.00$8,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Radius Health (NASDAQ:RDUS)
Latest Headlines for Radius Health (NASDAQ:RDUS)
Source:
DateHeadline
finance.yahoo.com logoRadius Health Receives FDA Fast Track Designation for Elacestrant (RAD1901)
finance.yahoo.com - October 19 at 8:05 AM
americanbankingnews.com logoContrasting Radius Health (RDUS) & Leap Therapeutics (LPTX)
www.americanbankingnews.com - October 19 at 6:28 AM
finance.yahoo.com logoRadius Health, Inc. – Value Analysis (NASDAQ:RDUS) : October 13, 2017
finance.yahoo.com - October 14 at 7:14 AM
nasdaq.com logoRadius Health to Present First Health Economics Data on TYMLOS™ (abaloparatide) Injection at the Academy of ... - Nasdaq
www.nasdaq.com - October 13 at 8:35 AM
prnewswire.com logoBiotech Stocks on Investors' Radar -- Tesaro, Trevena, Omeros, and Radius Health - PR Newswire (press release)
www.prnewswire.com - October 13 at 8:35 AM
feeds.benzinga.com logoRadius Health to Present First Health Economics Data on TYMLOS™ (abaloparatide) Injection at the Academy of Managed Care Pharmacy Nexus 2017
feeds.benzinga.com - October 13 at 8:25 AM
finance.yahoo.com logoRadius Health, Inc. breached its 50 day moving average in a Bearish Manner : RDUS-US : October 12, 2017
finance.yahoo.com - October 12 at 8:50 AM
americanbankingnews.com logoRadius Health, Inc. (RDUS) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - October 11 at 10:54 AM
americanbankingnews.com logoRadius Health, Inc. (RDUS) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - October 8 at 7:20 PM
americanbankingnews.com logoRadius Health's (RDUS) "Neutral" Rating Reiterated at Goldman Sachs Group, Inc. (The)
www.americanbankingnews.com - October 6 at 8:34 PM
americanbankingnews.com logo Analysts Anticipate Radius Health, Inc. (RDUS) to Announce -$1.28 EPS
www.americanbankingnews.com - October 3 at 8:40 AM
zacks.com logoRadius (RDUS) Enrols First Patient in Breast Cancer Study
www.zacks.com - October 2 at 10:04 AM
streetinsider.com logoRadius Health (RDUS) Says it Initiated Phase 1 Trial of RAD140 for Treatment of Hormone Receptor Positive Breast Cancer
www.streetinsider.com - September 30 at 11:08 AM
streetinsider.com logoRadius Health (RDUS) Says it Initiated Phase 1 Trial of RAD140 for ... - StreetInsider.com
www.streetinsider.com - September 29 at 10:25 PM
americanbankingnews.com logoRadius Health, Inc. (RDUS) Receives "Positive" Rating from Maxim Group
www.americanbankingnews.com - September 29 at 9:02 AM
seekingalpha.com logoRadius Health (RDUS) Presents At Cantor Fitzgerald Global Healthcare Conference - Slideshow
seekingalpha.com - September 25 at 4:34 PM
globenewswire.com logoRadius Health to Present at Cantor Annual Global Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - September 22 at 9:06 PM
finance.yahoo.com logoRadius Health to Present at Cantor Annual Global Healthcare Conference
finance.yahoo.com - September 22 at 9:06 PM
nasdaq.com logoRadius Health is Now Oversold (RDUS)
www.nasdaq.com - September 20 at 8:15 AM
nasdaq.com logoRadius Health Inc (RDUS) President and CEO Jesper Hoiland Bought $199592 of Shares - Nasdaq
www.nasdaq.com - September 17 at 7:17 AM
americanbankingnews.com logoRadius Health, Inc. (RDUS) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - September 16 at 11:02 AM
finance.yahoo.com logoRadius Health Inc (RDUS) President and CEO Jesper Hoiland Bought $199,592 of Shares
finance.yahoo.com - September 16 at 1:40 AM
americanbankingnews.com logoJose Carmona Acquires 3,000 Shares of Radius Health, Inc. (RDUS) Stock
www.americanbankingnews.com - September 15 at 4:32 PM
americanbankingnews.com logoJesper Hoiland Acquires 6,100 Shares of Radius Health, Inc. (RDUS) Stock
www.americanbankingnews.com - September 15 at 4:30 PM
americanbankingnews.com logoGrowth N. V. Biotech Acquires 150,000 Shares of Radius Health, Inc. (RDUS) Stock
www.americanbankingnews.com - September 15 at 4:30 PM
seekingalpha.com logoBiotech Forum Daily Digest: Revisiting Radius Health - Seeking Alpha
seekingalpha.com - September 15 at 3:30 PM
seekingalpha.com logoRadius Health (RDUS) Presents At Morgan Stanley 15th Annual Global Healthcare Conference - Slideshow
seekingalpha.com - September 15 at 8:04 AM
seekingalpha.com logoRadius Health (RDUS) Presents at Morgan Stanley 15th Annual Global Healthcare Conference (Transcript) - Seeking Alpha
seekingalpha.com - September 13 at 8:38 PM
americanbankingnews.com logoInsider Buying: Radius Health, Inc. (RDUS) Major Shareholder Purchases 50,000 Shares of Stock
www.americanbankingnews.com - September 13 at 7:16 PM
globenewswire.com logoRadius Health Presents Positive Data for TYMLOS™ (abaloparatide) Injection from the ACTIVExtend Trial at ASBMR ... - GlobeNewswire (press release)
globenewswire.com - September 11 at 6:17 AM
americanbankingnews.com logoInsider Buying: Radius Health, Inc. (RDUS) Major Shareholder Acquires 50,000 Shares of Stock
www.americanbankingnews.com - September 7 at 4:24 PM
finance.yahoo.com logoRadius Health to Present at Morgan Stanley 15th Annual Global Healthcare Conference
finance.yahoo.com - September 7 at 8:17 AM
finance.yahoo.com logoRadius Health (RDUS) Down 12.7% Since Earnings Report: Can It Rebound?
finance.yahoo.com - September 5 at 5:47 AM
streetinsider.com logoRadius Health (RDUS) to Present Eight Abstracts at ASBMR Including Results of ACTIVE and ACTIVExtend Trials for TYMLOS Injection
www.streetinsider.com - September 3 at 6:12 AM
streetinsider.com logoRadius Health (RDUS) to Present Eight Abstracts at ASBMR ... - StreetInsider.com
www.streetinsider.com - September 2 at 8:00 AM
americanbankingnews.com logoRadius Health, Inc. (RDUS) Expected to Announce Earnings of -$1.28 Per Share
www.americanbankingnews.com - August 27 at 6:18 AM
nasdaq.com logoFirst Week of RDUS April 2018 Options Trading
www.nasdaq.com - August 26 at 8:46 AM
americanbankingnews.com logoRadius Health, Inc. (RDUS) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - August 22 at 11:12 AM
finance.yahoo.com logoRadius Health, Inc. – Value Analysis (NASDAQ:RDUS) : August 19, 2017
finance.yahoo.com - August 19 at 6:55 AM
americanbankingnews.com logoRadius Health, Inc. (RDUS) Major Shareholder Acquires $2,158,800.00 in Stock
www.americanbankingnews.com - August 18 at 1:22 PM
finance.yahoo.com logoSee what the IHS Markit Score report has to say about Radius Health Inc.
finance.yahoo.com - August 17 at 7:16 AM
americanbankingnews.com logoGrowth N. V. Biotech Buys 150,000 Shares of Radius Health, Inc. (RDUS) Stock
www.americanbankingnews.com - August 11 at 1:22 PM
seekingalpha.com logoRadius Health (RDUS) Presents At Canaccord Genuity 37th Annual Growth Conference - Slideshow
seekingalpha.com - August 11 at 7:59 AM
finance.yahoo.com logoIHS Markit Score Update: Drop in demand for ETFs holding Radius Health Inc is a negative sign for its shares
finance.yahoo.com - August 11 at 7:59 AM
finance.yahoo.com logoNew National Survey Reveals 82 Percent of Postmenopausal Women Miss Critical Connection Between Osteoporosis and Bone Fractures
finance.yahoo.com - August 11 at 7:59 AM
americanbankingnews.com logoCantor Fitzgerald Weighs in on Radius Health, Inc.'s FY2017 Earnings (NASDAQ:RDUS)
www.americanbankingnews.com - August 10 at 9:32 AM
americanbankingnews.com logoJefferies Group LLC Reiterates "Hold" Rating for Radius Health, Inc. (NASDAQ:RDUS)
www.americanbankingnews.com - August 9 at 11:26 AM
nasdaq.com logoRadius Health Announces Pricing of $300 Million of 3.00% Convertible Senior Notes due 2024 - Nasdaq
www.nasdaq.com - August 9 at 6:52 AM
nasdaq.com logoRSI Alert: Radius Health (RDUS) Now Oversold - Nasdaq
www.nasdaq.com - August 9 at 6:52 AM
finance.yahoo.com logoRadius Health Announces Pricing of $300 Million of 3.00% Convertible Senior Notes due 2024
finance.yahoo.com - August 9 at 6:52 AM

Social

Chart

Radius Health (RDUS) Chart for Thursday, October, 19, 2017

This page was last updated on 10/19/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.